Research Progress of PALB2 as a Susceptibility Gene for Breast Cancer
DOI:
https://doi.org/10.61173/vg6jv123Keywords:
PALB2, Breast cancer, BRCA2Abstract
Breast cancer is a complex disease that endangers women’s health worldwide. The research on breast cancer susceptibility genes is increasing, especially the newly discovered PALB2, which has aroused the enthusiasm of many researchers. At present, the correlation between PALB2 and breast cancer and the susceptibility of PABLB2 mutation to breast cancer has been a large number of clinical studies and clinical statistics around the world. PALB2 plays an important role in DNA homologous recombination repair (HRR) together with BRCA1 and BRCA2 in normal cells, and the mechanism of PALB2 mutation causing breast cancer is also related. The BRCA pathway inhibitor PARPi has also been well studied, but there is still room to study the specific resistance mechanism. In addition, PALB2 has been implicated in ovarian cancer, pancreatic cancer, and lung cell carcinoma. This provides a reference for the study of PALB2 in cancers other than breast cancer, and the role and mechanism of PALB2 can also be explored in more different cancers.
References
[1] Decker, Brennan et al. Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks. Journal of medical genetics 2017, 732-741.
[2] Lehrer, Steven, et al. EARS2 significantly coexpresses with PALB2 in breast and pancreatic cancer. Cancer treatment and research communications 2022, 100595.
[3] Yoshimura, Akiyo et al. Functions of Breast Cancer Predisposition Genes, Implications for Clinical Management. International journal of molecular sciences. 2022, 13 7481.
[4] Yang, Xin et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants, An International Study of 524 Families. Journal of clinical oncology 2020, 674-685.
[5] Boonen, Rick A C M et al. Functional analysis of genetic variants in the high-risk breast cancer susceptibility gene PALB2. Nature communications 2019.
[6] Xia, Bing et al. Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Molecular cell 2006, 719-729.
[7] Antoniou, Antonis C et al. Breast-cancer risk in families with mutations in PALB2. The New England journal of medicine 2014, 497-506.
[8] Abida, Wassim, et al. Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer, Analysis From the Phase II TRITON2 Study. Clinical cancer research, an official journal of the American Association for Cancer Research 2020, 2487-2496.
[9] Foo, Tzeh Keong, et al. BRCA1-Dependent and Independent Recruitment of PALB2-BRCA2-RAD51 in the DNA Damage Response and Cancer. Cancer research 2022, 3191-3197.
[10] Nepomuceno, Thales C et al. PALB2 Variants, Protein Domains and Cancer Susceptibility. Trends in cancer 2021, 188- 197.
[11] Liu, Jinhua et al. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy. Frontiers in pharmacology 2021, 731798.
[12] Ma, Hui et al. Disrupted BRCA1-PALB2 interaction induces tumor immunosuppression and T-lymphocyte infiltration in HCC through cGAS-STING pathway. Hepatology (Baltimore, Md.) 2023, 33-47.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
